Canigen L4
Active substance
ATC code
Species
Dogs.
Indications
For active immunisation of dogs against:
- L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion
- L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion
- L. interrogans serogroup Australis serovar Bratislava to reduce infection
- L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
Dose to be administered and administration route
Subcutaneous use.
Before use, ensure that the vaccine is at room temperature (15 °C – 25 °C).
Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.
Vaccination scheme:
Basic vaccination: The first vaccination can be administered from 6 to 9(*) weeks of age and the second vaccination from 10 to 13 weeks of age.
Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine.
(*) In case of high level of maternally derived antibodies, first vaccination is recommended at 9 weeks of age.
For simultaneous use with Canigen vaccines where authorised:
1 dose of a Canigen vaccine containing canine distemper virus strain Onderstepoort, canine adenovirus type 2 strain Manhattan LPV3, canine parvovirus strain 154 and/or canine parainfluenza virus strain Cornell components should be reconstituted with 1 dose (1 ml) of Canigen Lepto 4. The mixed vaccines should be at room temperature (15 °C – 25 °C) before they are administered by subcutaneous injection.
Adverse reactions
A mild and transient increase in body temperature (≤ 1 °C) has been observed very commonly in clinical studies for a few days after vaccination, with some pups showing less activity and/or a reduced appetite.
A small transient swelling at the site of injection (≤ 4 cm), which can occasionally be firm and painful on palpation, has been observed very commonly in clinical studies. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia, or immune-mediated polyarthritis have been reported in very rare cases.
A transient acute hypersensitivity reaction may occur in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be lifethreatening. If such reactions occur, appropriate treatment is recommended.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
